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INTRODUCTION
The incidence of cutaneous melanoma has increased
rapidly worldwide.1-5 Although it corresponds to only 4% of
all skin cancers, it accounts for 80% of skin cancer deaths.4
Because early detection of the disease is implicit in its cure
and only 14% of patients with metastatic disease survive
beyond 5 years,4-6 knowledge of factors that increase an
individual’s risk for developing melanoma and diagnosis at
an early stage of the disease have great prognostic
relevance.
The risk factors for developing melanoma are both genetic
and environmental, especially the presence of multiple
melanocytic nevi, dysplastic nevi and atypical mole syn-
drome (AMS), as the main clinical phenotypic susceptibil-
ity.4-9
In 1820, Norris10 described what is currently considered
in a family predisposed to melanoma. In 1978, Clark11
reported an increased incidence of cutaneous melanoma in
families with multiple melanocytic lesions, introducing the
melanoma tumor progression model from melanocytic
nevi.11,12 At the time, Clark used the term B-K mole syndrome
using the initials of the patients surnames.11 Currently, the
terms AMS, Dysplastic Nevus Syndrome and Familial
Atypical Multiple-Mole Melanoma Syndrome (FAMMM)
have been employed.12 In 1985, Elder13 extended the theory
of ‘‘nevus-melanoma’’ for sporadic dysplastic nevi as a
possible precursor to sporadic melanoma.
Several studies have shown that the presence of dysplas-
tic nevi considerably increases the risk of developing
melanoma, which demonstrates that these lesions, aside
from being precursors to disease are also important risk
markers.4,7,14-19 Nevertheless, the risk magnitude varies
among patients with this type of pigmented lesion.3,4,15,16,20
There are still controversies in the literature regarding the
nomenclature, clinical definition, dermoscopic characteris-
tics and histopathological, genetic and molecular patterns of
dysplastic nevi.4,8
In this literature review of dysplastic nevi and AMS, we
demonstrate the importance of a complete dermatological
examination for the evaluation and monitoring of patients
with dysplastic nevi and AMS and suggest criteria for
follow-up.
Epidemiology
Dysplastic nevi are relatively common in the general
population.8 Reports have described the prevalence ranging
from 2% to 53% in different studies, depending on the
diagnostic criteria (clinical or histological).8 A more accurate
estimate is considered to be about 2%-8% of Caucasians,
with a predilection for young individuals (less than 30 to 40
years of age).18 The frequency of dysplastic nevi in patients
with a history of melanoma is much higher: 34% to 59%.18
Evidence suggests that sun exposure, in addition to genetic
susceptibility, may increase the appearance of such
nevi.1,8,18
Data concerning the prevalence of AMS are difficult to
document in part due to the large variability in the
diagnostic criteria employed by different studies. Based on
estimates by the National Institutes of Health (NIH), it has
been estimated that about 32,000 individuals were carriers
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of AMS and familial melanoma in the United States in 1985,
while about 4 million had sporadic AMS.3,21
Genetics
AMS can be sporadic or hereditary, in which case
autosomal dominant inheritance is suggested with variable
expressivity and incomplete penetrance.22 To date, no
susceptibility gene has been identified for this syndrome.22
However, there are reports of associations between devel-
opment of AMS and changes in chromosomes 9p21 and
1p36.23 It was demonstrated that the presence of dysplastic
nevi increases the risk of melanoma in patients with
germline mutations in CDKN2A, the main genomic locus
of melanoma susceptibility.24,25 This genomic locus harbors
two important genes involved in cell cycle control,
senescence and apoptosis: p16 and p14ARF. The presence
of a susceptibility gene for the development of dysplastic
nevi was also observed on chromosome 7q21.3 in patients
with the p16 gene mutation in four families with familial
melanoma.20
A high incidence of somatic mutations of the BRAF gene
has also been detected in patients with dysplastic nevi and
primary melanomas.8 Moreover, melanocytic lesions of
rapid growth or development are more likely to have
mutations in this gene when compared to lesions without a
history of changes in their clinical aspects.8
Other genetic changes described in dysplastic nevi
include microsatellite instability, loss of heterozygosity
(LOH) and increased activity of the telomerase enzyme.12
Currently, it is known that only 20% to 30% of melanomas
arise in association with a melanocytic nevus, which
indicates that the Clark’s theory of progression can explain
only one of the paths from carcinogenesis to melanoma.26
Patients with dysplastic nevi may have a reduced ability
to repair UV-induced DNA damage.8
Although genetic and environmental interactions are
clearly involved in the melanocytic transformation patho-
genesis, the understanding of its molecular mechanisms still
remains incomplete.8
Clinical Diagnosis
Clinically, a dysplastic nevus is most often a spotted
lesion of 5 mm or more in diameter, with irregular and
poorly defined borders and variable shades of brown, and it
may present a reddish hue, with bleaching accomplished
using vitropressure.18 It often presents a central papule,
surrounded by a pigmented macular ring, giving the
appearance of a ‘‘fried egg’’.18 Thus, there is considerable
overlap with the ABCDE rule used for clinical diagnosis of
melanoma, namely, A: asymmetry, B: irregular borders C:
varied colors, D: diameter . 6 mm and E: elevation
(simultaneous presentation of macular and papular compo-
nents) (Figure 1).3,12,18
Dysplastic nevi may be present in any topography,
including double-covered areas (such as buttocks and
breasts), iris, instep and scalp.1,3,18,27 However, despite their
occurrence in these unusual areas, the torso is the most
common site for dysplastic nevi to develop.18,27 These
lesions usually occur in puberty but can present in
prepubescent children and in adults, and they may remain
relatively dynamic in adulthood or disappear.3,18,27 It is also
observed that the number of dysplastic nevi correlates
directly with the total count of melanocytic nevi of the
individual.27 Furthermore, from a clinical standpoint, it is
known that the atypical nevus can evolve from a seemingly
common melanocytic nevus or show atypical features from
its first emergence.27 As dynamic lesions, they may become
progressively more or less atypical in their clinical aspect.27
Although the majority of dysplastic nevi remain stable,
regress over time or evolve benignly, monitoring of these
lesions is essential. Their prophylactic excision is not
justified.8,27
AMS has already been described by several authors and
institutions based on clinical characteristics of patients and
their personal and/or family history of melanoma, with or
without histopathological confirmation of an atypical
nevus.3
According to Newton et al.1, AMS can be defined through
a scoring system, assigning one point for each feature, as
seen in Table 1. Patients with scores greater than or equal to
Figure 1 - Macroscopic image of two melanocytic lesions whose
characteristics are superimposed by the ABCD rule (asymmetry,
irregular borders, varied coloration, diameter greater than
6 mm): Left - dysplastic nevus; Right – cutaneous melanoma.
Table 1 - AMS classifications and their specific
characteristics.
CLASSIFICATION CHARACTERISTICS COMMENTS
Newton et al.
(1993)
1) two or more clinically atypical
nevi, 2) more than 100 nevi in
patients between 20 and 50 years
of age, 3) more than 50 nevi in
patients under 20 years of age or
more than 50 years of age, 4)
more than one nevus in buttocks
or instep, 5) nevi on the anterior
scalp, 6) one or more pigmented
lesions in the iris.
Scores greater
than or equal
to 3
characterize
the AMS
phenotype.
Classical (1990) 1) 100 or more melanocytic nevi,
2) one or more melanocytic
nevi greater than or equal to
8mm in its largest diameter,
and 3) one or more clinically
atypical melanocytic nevi
Requires all
features for
diagnosis. High
demand for
total count of
nevi for
classification;
low sensitivity
National
Institutes of
Health (NIH) –
Consensus
1992
1) occurrence of melanoma in one
or more first or second degree
relatives, 2) a large number of
melanocytic nevi, often greater
than 50, some being atypical and
often variable in size, and 3)
melanocytic nevi that present
certain histological features *
(*defined by Consensus)
Requires
histological
specific
features, still
controversial
and considers
only patients
with family
histories of
melanoma
Adapted from Newton et al.1993 1, Slade et al.1995 3
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three are considered carriers of AMS phenotype1 (Figure 2).
Other classifications have also been described, including the
so-called Classical AMS which includes patients with over
100 nevi, at least one lesion with clinical features of an
atypical nevus and one nevus 8 mm or more in its largest
diameter.3,28 The classification devised by the National
Institutes of Health (NIH) includes only those patients with
a familial history of melanoma (Table 1).29
The Kraemer16 and Rigel15 classifications indicate the
magnitude of the risk of melanoma for patients with AMS,
which appears to be most dependent on a personal and / or
family history of melanoma and for some cases a relative
risk (RR) of 1269 has been reported3 (Figure 3). According to
Kraemer et al.16, AMS patients can be classified into the
following types according to their heredity characteristics:
type A: sporadic AMS; type B: familial AMS; type C:
sporadic AMS with personal history of melanoma; type D1:
familial AMS, with one family member with a history of
melanoma; type D2: familial AMS with two or more family
members with a history of melanoma. The different disease
types indicate various risks of developing cutaneous
melanoma.
Rigel et al.15,30 classified AMS patients into four risk
groups according to the presence or absence of a personal
Figure 2 - Body mapping of a male patient, 34 years of age, 256 nevi selected for follow-up. Presents 3 criteria for AMS: more than 100
nevi, presence of more than 2 clinically dysplastic nevi and nevi on the buttocks.
Figure 3 - Kraemer and Rigel Classifications.
CLINICS 2011;66(3):493-499
Silva JH et al.
495
and/or family history of melanoma, giving one point to the
personal history of melanoma and two points for family
history of melanoma (Figure 3). The sum of the points gives
rise to the following groups and their respective relative
risks (RR) of developing melanoma: group 0: no points (RR:
2-92); group I: 1 point (RR: 8-127); group II: 2 points (RR: 33-
444); group III: 3 points (RR: 85-1269) (Figure 3).3,15,30
Thus, the presence of dysplastic nevi and AMS can be
considered as a spectrum of phenotypic expressions, which
confers to the carriers different risks of developing
melanoma.3,21 The risk spectrum varies from individuals
with sporadic dysplastic nevi, with no personal or
family history of melanoma, to the opposite extreme with
AMS individuals belonging to families in which two or
more members had melanoma, forming the so-called
familial atypical multiple-mole melanoma syndrome
(FAMMM).3,4,15,16,20,31
Besides presenting an increased risk of developing
cutaneous melanoma, AMS patients tend to present
neoplasia in unusual sites (such as the scalp) at an earlier
age than the non-carriers of the syndrome.1 There is also
increased risk for multiple melanomas and non-cutaneous
melanoma in those patients, such as ocular melanoma.8
Prospective studies show that the risk of melanoma in
members of families affected by AMS and FAMMM is
significant, with an estimated cumulative risk of 49% in
individuals 10 to 50 years of age and 82% in individuals 72
years of age.32
Histopathology
Although the histopathologic exam is considered to be the
gold standard for the diagnosis of melanocytic tumors, there
are limitations in the histologic distinction between early
melanomas and dysplastic nevi.12 In several studies, the
reproducibility in grading the atypia remains poor to
moderate, due to a lack of uniform criteria among
dermatopathologists.12,18
Based on the World Health Organization (WHO) and
NIH consensus, the histopathologic diagnosis of dysplastic
nevi (Figure 4) is based on the major criteria (mandatory)
and minor criteria (at least two must be present)23, detailed
in Table 2.
Diagnosis and Follow-Up
The clinical distinction between benign and malignant
pigmented lesions can be challenging in some cases.
However, as demonstrated by several studies, the use of
dermoscopy, an auxiliary noninvasive diagnostic method in
the clinical dermatological examination, it is possible to
increase the diagnostic accuracy of pigmented lesions,
including melanomas.33 In a meta-analysis of 27 studies,
Kittler et al.34 demonstrated a 49% improvement in
diagnostic accuracy, with 6% and 19% increases in
specificity and sensitivity, respectively. Moreover, in a
randomized study to evaluate the procedure adopted for
pigmented lesions using the dermatoscope, Carli et al.35
demonstrated a reduction in the number of patients referred
for biopsy (9.0% versus 15.6%). In recent decades, several
diagnostic algorithms have been described in dermoscopy
for the recognition of melanoma including the Pattern
Analysis Method, the ABCD rule, the 7-Point Checklist, the
CASH algorithm, the Menzies method and others.33 In a
comparison of three algorithms (Pattern Analysis, ABCD
Rule and the 7-Point Checklist), Annensi et al.36 demon-
strated that the Pattern Analysis method provided the
highest sensitivity, specificity and accuracy for the diagnosis
of thin melanomas.
Although they do not solve all the diagnostic difficulties
surrounding the atypical nevus, dermoscopic evaluation
and especially monitoring greatly improve the management
of these lesions of uncertain behavior.12
Both benign and indeterminate patterns can be identified
in dysplastic nevi, using dermoscopy37 (Figure 5). The
features most commonly found in dysplastic nevi, described
by the Pattern Analysis are the following: atypical pigment
network, areas of irregular and peripheral depigmentation,
pigmentation with central heterogeneity and abrupt termi-
nation and brown globules of different shapes and sizes
with irregular distribution.38,39 In dysplastic nevi, black dots
in the periphery, pseudopods, branched streaks and blue-
whitish veil are rarely found. These structures are more
frequently found in cutaneous melanoma.38,39
The pigmented skin lesions with very atypical or
nonspecific dermoscopic patterns should be excised for
definitive diagnosis by pathology.40,41
Moreover, in patients with multiple nevi, including those
with dysplastic nevi and AMS, who tend to have a large
number of evolving lesions, dermoscopy alone is not always
sufficient to distinguish between benign lesions or new
individually suspicious ones.8,42 Thus, the monitoring of
nevi in at-risk patients by total body mapping and digital
dermoscopy is crucial for both early identification of
Figure 4 - Histopathologic exam of atypical nevus showing focal
atypia of melanocytes, fusion of epithelial cones and concentric
lamellar fibrosis. Optical microscopy image with high magnifica-
tion (40X).
Table 2 - Dyspalstic Nevus – Histopathological Criteria
(NIH).
Major Criteria (mandatory)
Lentiginous or contiguous melanocytic hyperplasia
Focal melanocytic atypia
Minor Criteria (at least 2)
‘Shoulder phenomenon’
Fusion of epithelial cones
Subepidermal concentric lamellar fibrosis
Superficial perivascular lymphocytic inflammatory infiltrate
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malignant lesions and the minimization of unnecessary
biopsies of benign lesions.43,44
Total body mapping and digital dermoscopy allow for
storage of macroscopic and dermoscopic images for
comparison over time. Follow-up procedures using this
technique can be accomplished in short and long term. The
long-term follow-up is performed at intervals of 9 to 12
months and is more suitable for risk patients with multiple
nevi, including those with AMS.45 In this type of follow-up,
changes that indicate lesion excision include the following:
growth, change in shape, regression, changes in color and
appearance of dermoscopic structures known to be asso-
ciated with melanomas.34 In short term follow-up, the
revaluation of the lesions must occur within 3 months from
the first visit and is indicated for suspicious melanocytic
lesions that have no dermoscopic features of melanoma.
These include clinically moderate atypical lesions and less
atypical ones that present a change history.45 The lesion
should be excised when it presents any kind of morpholo-
gical change except alterations in the number of milia cysts
or global aspect of pigmentation.46
Follow-up recommendations for AMS patients
The importance of early identification and treatment
of melanoma is well established, as evidenced by the
differences between the survival curves of patients at
different stages as determined by the American Joint
Committee on Cancer (AJCC) that show a 5-year survival
rate around 95% for patients in Stage I and 15% for patients
in Stage IV.6,47 Therefore, follow-up strategies for high risk
populations such as those with AMS are justified by
maximizing opportunities for detecting melanoma in its
early stages.3
As the majority of melanomas arise de novo and only
about 20-30% arise in a pre-existing nevus, atypical
melanocytic nevi are considered important risk markers.26
Thus, prophylactic excision of all clinically dysplastic nevi
in a subject with multiple nevi is unfounded and often not
feasible.18 This approach could give the patient a false sense
of security since their increased risk of melanoma persists
even with the removal of all melanocytic lesions.
A periodic dermatological examination is generally
recommended for patients with dysplastic nevi or AMS,
ranging from an examination every 3-12 months, depending
on a patient’s position within the risk spectrum described
above.3 Thus, some authors propose that patients of Rigel’s
group 0 be examined annually, while those with higher risk
(Rigel I, II or III) should be evaluated by a dermatologist
every 3 to 6 months.3 According to Tucker et al.32, the risk of
melanoma for patients with AMS in families predisposed to
melanoma begins to increase at around 10 years of age and
so it is recommended that monitoring begin at puberty.3
Physical examination of the entire integument is essential
because most melanomas occur on covered areas and
previous studies have demonstrated that the detection of
melanoma was 6 times more frequent in patients who
undressed completely.3,48
As mentioned above, dermoscopy increases the dia-
gnostic accuracy of melanocytic neoplasias, and its imple-
mentation is recommended during dermatologic consulta-
tion.48,49,50,51
However, even with the aid of a dermatoscope, identifi-
cation of new lesions and significant changes in nevi in
individuals with multiple pigmented lesions and AMS can
be challenging, making total body mapping and digital
dermoscopy of great benefit to the diagnostic process.43,44 In
Figure 5 - Digital dermoscopy (20X) of melanocytic lesions that have similar dermatoscopic appearance (A , B; C , D): A) compound
melanocytic nevus; B) dysplastic nevus; C) dysplastic junctional nevus with severe atypia, D) thin melanoma.
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the protocol followed by the Dermoscopy Clinic of the Skin
Oncology Department of Hospital AC Camargo, risk
patients are reevaluated 3 months after the first visit, with
a third evaluation 6 months after the last one, followed by
annual tracking. In a survey including risk patients who
underwent their first examination between March 2003 and
November 2007, a total of 255 patients were observed, 53 of
whom presented with AMS. 14,307 lesions were followed-
up and 355 showed changes over time (2.5%). Of these, 10
lesions were diagnosed as cutaneous melanoma, all pre-
senting a thickness under 1 mm, including 5 in situ
melanomas. The main risk factors associated with malignant
transformation were personal history of melanoma (OR
11.3) and AMS (OR 5.1) (unpublished data).
Any suspicious lesion and/or significant change should
be considered for biopsy, preferably by excision with
conservative surgical margins (2 mm) providing adequate
samples for histopathological evaluation.3,8 Non-surgical
alternatives such as topical 5-fluorouracil, systemic isotre-
tinoin, topical tretinoin with or without hydrocortisone,
topical imiquimod and laser ablation are not effective or
safe for the removal of suspicious lesions and are not
recommended.8,52.
Education of patients with dysplastic nevi or AMS in
self-examination of the skin is relatively simple and
inexpensive, and some studies have suggested increased
detection of thin melanomas or greater survival in patients
who performed self-examination in comparison with those
who did not.18 Slade et al.3 recommend self-examination of
the skin every 2 to 3 months. Given the increased prevalence
of uveal melanoma in patients with AMS, some authors
recommend routine annual assessment by an ophthalmol-
ogist.53,54
Ultraviolet light is known to be ‘‘nevogenic’’ and appears
to contribute to the emergence of dysplastic nevi.3,55
Furthermore, UV radiation acts as an initiator and promoter
in the process of malignant transformation of melanocytes.3
It was demonstrated that patients with hereditary AMS
have reduced abilities to repair DNA damage induced by
ultraviolet light.56,57 Therefore, the patient should avoid
exposure to sunlight or artificial ultraviolet light (such as
tanning beds) and use physical protection in the prevention
of sunburn.3,18 Although it has not been documented that
the use of sunscreen prevents the emergence of dysplastic
nevi or decreases the risk of developing melanoma, it has
been shown that a sunscreen with a Sun Protection Factor of
at least 15 reduces the incidence of actinic keratoses and
decreases the development of melanocytic nevi.3,18 The
patient must be advised not to use sunscreen in order to
prolong exposure, which may in fact increase the risk of
developing melanoma.3,19
Prospective studies show that the risk of melanoma in
families of patients with AMS is considerable.32 In addition,
many patients initially considered as having sporadic AMS
actually belong to families with AMS.3 Therefore, it is
recommended that first-degree relatives of AMS patients be
examined by a dermatologist for the presence of dysplastic
nevi, AMS or melanoma.
Because carriers of AMS and FAMMM evidence an
association between melanoma and other internal malig-
nancies (pancreatic neoplasia, central nervous system
tumors, breast cancer)3, evaluation by a specialist is there-
fore recommended in the case of suspected symptoms in
these patients.
Currently, there is no scientific basis for performing
genetic testing in AMS patients except in research proto-
cols.18,58,59
CONCLUSION
AMS demonstrably increases the risk of developing
melanoma, a malignant neoplasm for which incidence have
increased significantly in recent decades and for which early
diagnosis is of great importance in the prognosis of the
disease.4,59 The identification of patients with AMS, the
main clinical risk factor, allows them to be included in short
and long term monitoring programs, aimed at early
detection of suspicious lesions and the consequent reduc-
tion in mortality associated with advanced melanoma.42 In
addition, a prevention program could contribute to
increased awareness and changes in risk behavior, mini-
mizing the environmental risk not only for patients but also
for their families.
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